QPPV.COM KNOWLEDGE ASSESSMENT

Ongericimab: Classification, Mechanism, Evidence and Pharmacovigilance

Test your understanding of the concepts covered by Ongericimab: Classification, Mechanism, Evidence and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which description of the phase 3 study is accurate?

An open-label cardiovascular-outcomes study in which myocardial infarction was the primary endpoint. A randomised, double-blind, 52-week study in Chinese adults above LDL-C targets on stable, optimised lipid-lowering therapy, with LDL-C change at week 24 as the primary endpoint. A short-term pharmacokinetic study in healthy volunteers with LDL-receptor expression as the primary endpoint. A trial restricted to patients with familial hypercholesterolaemia and no background lipid-lowering therapy.

Question 2 of 10 A patient taking both a statin and ongericimab reports muscle pain. What is the best initial pharmacovigilance approach?

Assign the event to ongericimab because it is the newer medicine. Assign the event to the statin because muscle symptoms are always caused by statins. Document both treatments, including statin dose and changes, laboratory values, clinical evaluation, and event chronology before drawing conclusions. Exclude the event from reporting unless the LDL-C target was not reached.

Question 3 of 10 During an audit of a report stating 'high cholesterol despite treatment,' which evidence should the audit trail ideally contain?

A verified lipid result alone, because treatment history is not relevant to response. Verified values, dose and administration history, concomitant therapy, adherence, possible secondary causes, and follow-up. The reporter's conclusion that the product failed, without supporting records. Only a statement that the patient received a prescription.

Question 4 of 10 Which sequence best describes how ongericimab lowers LDL-C?

It binds LDL receptors and prevents them from removing LDL particles from the circulation. It binds PCSK9, reduces PCSK9-mediated LDL-receptor degradation, and leaves more receptors available to clear LDL particles. It inhibits cholesterol synthesis directly in the liver and thereby increases PCSK9 activity. It binds circulating LDL particles and removes them through antibody-mediated destruction.

Question 5 of 10 Which statement about the authorised population and evidence is most appropriate?

Evidence from another population automatically expands the China authorisation. A trial in a related population may inform development, but does not itself expand the authorised indication. The China indication applies to all adults with any elevation in LDL-C, regardless of treatment history. The LDL-C trial endpoint establishes use for cardiovascular event prevention in populations not studied.

Question 6 of 10 What is the most appropriate interpretation when two antibodies target PCSK9?

They must have the same active substance because their target is identical. Their indications and safety information can be assumed to be interchangeable. A shared target does not establish that they are the same substance, biosimilars, or have interchangeable labels. They can be considered therapeutically equivalent without product-specific evidence.

Question 7 of 10 Which patient profile most closely matches the China indication described in the article?

An adult with non-familial primary hypercholesterolaemia who remains above the recommended LDL-C target despite moderate- or high-dose statin treatment. An adult with familial hypercholesterolaemia receiving no lipid-lowering therapy. An adult who cannot tolerate any statin and is seeking ongericimab monotherapy. A child with mixed dyslipidaemia whose LDL-C is already at the recommended target.

Question 8 of 10 Which description most accurately classifies ongericimab?

A small-molecule inhibitor of cholesterol synthesis. A fully human IgG1 monoclonal antibody against PCSK9. A biosimilar version of any previously authorised anti-PCSK9 antibody. A recombinant LDL receptor replacement protein.

Question 9 of 10 A patient reports injection-site symptoms after an ongericimab dose. Which information is most useful to document for case assessment?

Only the patient's most recent LDL-C result. Dose, route, symptom onset, treatment provided, and outcome. Only whether the patient has previously used another anti-PCSK9 antibody. The presumed mechanism of the reaction, without chronology or clinical details.

Question 10 of 10 How should the reported placebo-adjusted least-squares mean LDL-C difference of −67.7% for the 150 mg every-two-weeks group be interpreted?

As the percentage of participants who avoided a cardiovascular event. As a placebo-adjusted estimate of LDL-C change at week 24 in the studied population and treatment context. As proof that every treated patient experienced exactly a 67.7% LDL-C reduction. As the relative reduction in all serious adverse reactions over 52 weeks.

Ongericimab: Classification, Mechanism, Evidence and Pharmacovigilance

Cookie Settings